-
公开(公告)号：US06844345B2
公开(公告)日：2005-01-18
申请号：US10092751
申请日：2002-03-07
申请人： Paul Hebeisen , Patrizio Mattei , Marc Muller , Hans Richter , Stephan Roever , Sven Taylor
发明人： Paul Hebeisen , Patrizio Mattei , Marc Muller , Hans Richter , Stephan Roever , Sven Taylor
IPC分类号： A61K31/337 , A61K31/4985 , A61P3/00 , A61P3/04 , A61P3/10 , A61P7/02 , A61P9/00 , A61P11/00 , A61P13/02 , A61P25/00 , A61P25/06 , A61P25/08 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P25/32 , A61P29/00 , A61P43/00 , C07D487/04
CPC分类号： C07D487/04
摘要： The present invention provides piperazine derivatives in accordance with formula (I) as well as salts, hydrates and esters thereof. The substituent designations are as provided in the specification. The compounds of the present invention can be used in the treatment of type II diabetes or obesity.
摘要翻译： 本发明提供根据式（I）的哌嗪衍生物及其盐，水合物和酯。 取代基名称如本说明书中所提供。 本发明的化合物可用于治疗II型糖尿病或肥胖症。
-
![Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles](/abs-image/US/2005/10/27/US20050239789A1/abs.jpg.150x150.jpg)
2.发明申请公开(公告)号：US20050239789A1
公开(公告)日：2005-10-27
申请号：US11169079
申请日：2005-06-28
申请人： Jonathan Bentley , Paul Hebeisen , Patrizio Mattei , Marc Muller , Hans Richter , Stephan Roever , Sven Taylor
发明人： Jonathan Bentley , Paul Hebeisen , Patrizio Mattei , Marc Muller , Hans Richter , Stephan Roever , Sven Taylor
IPC分类号： A61K31/337 , A61K31/4985 , A61K45/00 , A61P1/00 , A61P3/04 , A61P3/10 , A61P7/02 , A61P9/00 , A61P11/00 , A61P13/00 , A61P15/00 , A61P25/00 , A61P25/06 , A61P25/08 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P25/32 , C07D487/04 , A61K31/498
CPC分类号： C07D487/04
摘要： The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a]indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.
摘要翻译： 本发明涉及1,2,3,4,10,10a，六氢吡嗪并[1,2-a]吲哚衍生物及其药学上可接受的盐，溶剂合物和酯，其中R 1〜 具有权利要求1给出的含义以药物制剂的形式用于治疗或预防中枢神经系统病症，对中枢神经系统的损害，心血管疾病，胃肠道 疾病，尿崩症，肥胖和睡眠呼吸暂停。
-
![Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles](/abs-image/US/2007/08/07/US07253281B2/abs.jpg.150x150.jpg)
3.发明授权公开(公告)号：US07253281B2
公开(公告)日：2007-08-07
申请号：US11169079
申请日：2005-06-28
申请人： Jonathan Mark Bentley , Paul Hebeisen , Patrizio Mattei , Marc Muller , Hans Richter , Stephan Roever , Sven Taylor
发明人： Jonathan Mark Bentley , Paul Hebeisen , Patrizio Mattei , Marc Muller , Hans Richter , Stephan Roever , Sven Taylor
IPC分类号： C07D487/04 , A61K31/4985
CPC分类号： C07D487/04
摘要： The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a]indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.
摘要翻译： 本发明涉及1,2,3,4,10,10a，六氢吡嗪并[1,2-a]吲哚衍生物及其药学上可接受的盐，溶剂合物和酯，其中R 1〜 具有权利要求1给出的含义以药物制剂的形式用于治疗或预防中枢神经系统病症，对中枢神经系统的损害，心血管疾病，胃肠道 疾病，尿崩症，肥胖和睡眠呼吸暂停。
-
![Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles](/abs-image/US/2007/05/10/US20070106076A1/abs.jpg.150x150.jpg)
4.发明申请Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles 审中-公开抗肥胖症1,2,3,4,10,10a-六氢吡嗪并[1,2-a]吲哚公开(公告)号：US20070106076A1
公开(公告)日：2007-05-10
申请号：US11649132
申请日：2007-01-03
申请人： Jonathan Bentley , Paul Hebeisen , Patrizio Mattei , Marc Muller , Hans Richter , Stephan Roever , Sven Taylor
发明人： Jonathan Bentley , Paul Hebeisen , Patrizio Mattei , Marc Muller , Hans Richter , Stephan Roever , Sven Taylor
IPC分类号： C07D487/04 , A61K31/498
CPC分类号： C07D487/04
摘要： The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a] indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.
摘要翻译： 本发明涉及1,2,3,4,10,10a，六氢吡嗪并[1,2-a]吲哚衍生物及其药学上可接受的盐，溶剂合物和酯，其中R 1〜 具有权利要求1给出的含义以药物制剂的形式用于治疗或预防中枢神经系统病症，对中枢神经系统的损害，心血管疾病，胃肠道 疾病，尿崩症，肥胖和睡眠呼吸暂停。
-
公开(公告)号：US06610685B2
公开(公告)日：2003-08-26
申请号：US10017978
申请日：2001-12-14
申请人： Jonathan Mark Bentley , Michael John Bickerdike , Paul Hebeisen , Guy Anthony Kennett , Sean Lightowler , Patrizio Mattei , Jacques Mizrahi , Timothy James Morley , Jean-Marc Plancher , Hans Richter , Stephan Roever , Sven Taylor , Steven Paul Vickers
发明人： Jonathan Mark Bentley , Michael John Bickerdike , Paul Hebeisen , Guy Anthony Kennett , Sean Lightowler , Patrizio Mattei , Jacques Mizrahi , Timothy James Morley , Jean-Marc Plancher , Hans Richter , Stephan Roever , Sven Taylor , Steven Paul Vickers
IPC分类号： C07D48704
CPC分类号： C07D487/04
摘要： The present invention is a chemical compound of formula (I) or a pharmaceutically acceptable salt, solvate and ester thereof, wherein R1 to R4 and n are as defined in the specification. A compound of formula 1 is useful as a pharmaceutical composition for the treatment or prevention of disorders of the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes, obesity and sleep apnoea.
摘要翻译： 本发明是式（I）化合物或其药学上可接受的盐，溶剂化物和酯，其中R1至R4和n如说明书中所定义。 式1的化合物可用作治疗或预防中枢神经系统疾病，心血管疾病，胃肠道疾病，糖尿病，肥胖症和睡眠呼吸暂停的药物组合物。
-
6.发明授权1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivatives 失效1,2,3,4,9,9a-六氢-2,4a，5-三氮杂芴和1,2,3,4-四氢-2,4a，5-三唑 - 芴衍生物公开(公告)号：US07098337B2
公开(公告)日：2006-08-29
申请号：US10350616
申请日：2003-01-24
申请人： David Reginald Adams , Jonathan Mark Bentley , Toby Jonathan Blench , Paul Hebeisen , Nathaniel Julius Thomas Monck , Hans Richter , Stephan Roever , Jonathan Richard Anthony Roffey , Sven Taylor
发明人： David Reginald Adams , Jonathan Mark Bentley , Toby Jonathan Blench , Paul Hebeisen , Nathaniel Julius Thomas Monck , Hans Richter , Stephan Roever , Jonathan Richard Anthony Roffey , Sven Taylor
IPC分类号： C07D471/14 , A61K31/4985 , A61P3/04
CPC分类号： C07D471/14
摘要： The present invention relates to compounds of formula (I) as well as pharmaceutically acceptable salts, solvates and esters thereof. These compounds can be used to prepare pharmaceutical compositions for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes, obesity and sleep apnoea.
摘要翻译： 本发明涉及式（I）化合物及其药学上可接受的盐，溶剂化物和酯。 这些化合物可用于制备用于治疗或预防中枢神经系统疾病，中枢神经系统损害，心血管疾病，胃肠道疾病，糖尿病，肥胖症和睡眠呼吸暂停的药物组合物。
-
![Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles](/abs-image/US/2005/08/23/US06933387B2/abs.jpg.150x150.jpg)
7.发明授权公开(公告)号：US06933387B2
公开(公告)日：2005-08-23
申请号：US10396242
申请日：2003-03-25
IPC分类号： A61K31/337 , A61K31/4985 , A61K45/00 , A61P1/00 , A61P3/04 , A61P3/10 , A61P7/02 , A61P9/00 , A61P11/00 , A61P13/00 , A61P15/00 , A61P25/00 , A61P25/06 , A61P25/08 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P25/32 , C07D487/04
CPC分类号： C07D487/04
摘要： The present invention is directed to 1,2,3,4,10,10a-hexahydropyrazino [1,2-a]indole derivatives of formula (I): as well as pharmaceutically acceptable salts, hydrates and esters thereof, wherein the substituents have the meanings provided in the specification. Compounds of the present invention may be used in the treatment or prevention of obesity or Type II diabetes.
摘要翻译： 本发明涉及式（I）的1,2,3,4,10,10a-六氢吡嗪并[1,2-a]吲哚衍生物：及其药学上可接受的盐，水合物和酯，其中取代基具有 说明书中提供的含义。 本发明的化合物可用于治疗或预防肥胖或II型糖尿病。
-
8.发明授权Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity 失效吗啉衍生物作为治疗肥胖症的5HT2C受体激动剂公开(公告)号：US07323466B2
公开(公告)日：2008-01-29
申请号：US11332103
申请日：2006-01-13
申请人： Jonathan Mark Bentley , Claire Elizabeth Dawson , Wolfgang Guba , Paul Hebeisen , Nathaniel Monck , Robert Mark Pratt , Hans Richter , Stephan Roever , Vicki Ruston
发明人： Jonathan Mark Bentley , Claire Elizabeth Dawson , Wolfgang Guba , Paul Hebeisen , Nathaniel Monck , Robert Mark Pratt , Hans Richter , Stephan Roever , Vicki Ruston
IPC分类号： A61K31/5375 , C07D265/30
CPC分类号： C07D265/30
摘要： The present invention refers to chemical compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5 have the significance given in claim 1. These compounds can be used for the preparation of medicaments.
摘要翻译： 本发明涉及式（I）的化合物及其药学上可接受的盐和酯，其中R 1至R 5具有权利要求1中给出的含义。 这些化合物可用于制备药物。
-
9.发明授权Tetracyclic 6 azapyrazinoindolines as 5HT2C receptor agonists for obesity 失效四环六氮嗪基吲哚啉作为5HT2C受体激动剂用于肥胖公开(公告)号：US07547699B2
公开(公告)日：2009-06-16
申请号：US11412501
申请日：2006-04-26
申请人： Paul Hebeisen , Nathaniel Monck , Hans Richter , Stephan Roever
发明人： Paul Hebeisen , Nathaniel Monck , Hans Richter , Stephan Roever
IPC分类号： A01N43/60
CPC分类号： C07D471/22 , C07D491/22 , C07D495/22
摘要： The present invention refers to chemical compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5 have the significance given in claim 1. These compounds can be used for the preparation of medicaments.
摘要翻译： 本发明涉及式（I）的化合物及其药学上可接受的盐和酯，其中R1至R5具有权利要求1中给出的含义。这些化合物可用于制备药物。
-
公开(公告)号：US07208494B2
公开(公告)日：2007-04-24
申请号：US10876954
申请日：2004-06-25
IPC分类号： A01N43/58 , A01N43/60 , A61K31/50 , A61K31/495 , C07D471/00
CPC分类号： C07D471/14
摘要： The present invention provides piperazine derivatives of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5 have the significance given in the description. They can be used for the treatment of obesity.
摘要翻译： 本发明提供式（I）的哌嗪衍生物及其药学上可接受的盐和酯，其中R 1至R 5具有说明书中给出的含义。 它们可用于治疗肥胖。
-
-
-
-
-
-
-
-
-
搜索结果
105 条记录 (耗时 0.033 秒)
